LA JOLLA INSTITUTE FOR IMMUNOLOGY: Single Audit Reports and Findings
LA JOLLA INSTITUTE FOR IMMUNOLOGY filed 10 single audits between 2016 and 2025; the most recently observed auditor is Baker Tilly US, LLP (2025), and the 2025 report lists 0 findings. Data as of 2026-09-18.
Data as of Sep 18, 2026 · Source: Federal Audit Clearinghouse (public data)
Single audits by year
One row per audit year as the Federal Audit Clearinghouse accepted it. The auditor named is the one observed on that filing; LA JOLLA INSTITUTE FOR IMMUNOLOGY is recorded in LA JOLLA, California under EIN 330328688, and the Clearinghouse records it as a nonprofit.
| Audit year | Fiscal year end | Federal expended | Threshold applied | Auditor observed | Findings | MW / SD | FAC report |
|---|---|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $56,068,658 | $1,682,060 | Baker Tilly US, LLP | 0 | — | 2025-12-GSAFAC-0000419864 |
| 2024 | 2024-12-31 | $48,554,362 | $1,456,631 | MOSS ADAMS LLP | 0 | — | 2024-12-GSAFAC-0000369796 |
| 2023 | 2023-12-31 | $45,540,384 | $1,366,212 | MOSS ADAMS LLP | 0 | — | 2023-12-GSAFAC-0000042633 |
| 2022 | 2022-12-31 | $50,787,423 | $1,523,623 | MOSS ADAMS LLP | 0 | — | 2022-12-CENSUS-0000041447 |
| 2021 | 2021-12-31 | $54,364,542 | $1,630,936 | MOSS ADAMS LLP | 0 | — | 2021-12-CENSUS-0000041447 |
| 2020 | 2020-12-31 | $47,225,005 | $1,416,751 | MOSS ADAMS LLP | 0 | — | 2020-12-CENSUS-0000041447 |
| 2019 | 2019-12-31 | $42,229,605 | $1,266,888 | MOSS ADAMS LLP | 0 | — | 2019-12-CENSUS-0000041447 |
| 2018 | 2018-12-31 | $35,609,149 | $1,068,274 | MOSS ADAMS LLP | 0 | — | 2018-12-CENSUS-0000041447 |
| 2017 | 2017-12-31 | $34,049,162 | $1,021,475 | MOSS ADAMS LLP | 0 | — | 2017-12-CENSUS-0000041447 |
| 2016 | 2016-12-31 | $35,348,016 | $1,060,440 | MOSS ADAMS LLP | 0 | — | 2016-12-CENSUS-0000041447 |
Which federal programs did this organization report?
From the most recent accepted report. "Major" is the designation the auditor made under 2 CFR 200.518, not ours.
| ALN | Program | Expended | Major |
|---|---|---|---|
| 93.855 | Allergy and Infectious Diseases Research | $21,583,494 | Yes |
| 93.384 | Advanced Research Projects Agency for Health (ARPA-H) | $9,024,822 | Yes |
| 93.855 | Consortium for HIV/AIDS Vaccine Development | $3,238,434 | Yes |
| 93.RD | 75N93019C00001 IEDB-07 | $3,237,631 | Yes |
| 93.396 | Cancer Biology Research | $1,797,054 | Yes |
| 93.855 | Discovering Durable Pan-Coronavirus Immunity | $1,305,750 | Yes |
| 93.393 | Cancer Cause and Prevention Research | $1,198,942 | Yes |
| 93.RD | 75N93024C00057- Pneumonia | $1,112,154 | Yes |
| 93.RD | 75N93024C00056- PP | $1,101,593 | Yes |
| 93.855 | Flavivirus and Alphavirus ReVAMPP (FLARE) | $963,664 | Yes |
| 93.859 | Biomedical Research and Research Training | $843,299 | Yes |
| 93.395 | Cancer Treatment Research | $794,079 | Yes |
| 93.855 | Airway Inflammation and Airway Remodeling in Severe Asthma | $755,200 | Yes |
| 93.351 | Research Infrastructure Programs | $687,033 | Yes |
| 93.847 | Diabetes, Digestive, and Kidney Diseases Extramural Research | $489,056 | Yes |
| 93.855 | The Development and Evaluation of Pan-Coronavirus Vaccines | $454,526 | Yes |
| 93.855 | Transcription factor regulation of CD4 and CD8 T cell effector and memory differentiation and function | $438,409 | Yes |
| 93.353 | Personalized neuroblastoma vaccines | $433,449 | Yes |
| 93.RD | Collaborative Influenza Vaccine Innovation Centers (CIVICs) Component A: Vaccine Center | $424,546 | Yes |
| 93.847 | TWEAK/TNFSF12 and LIGHT/TNFSF14 interactions in allergic esophagitis remodeling | $392,472 | Yes |
| 93.RD | 75N93019C00001- CD3 | $389,000 | Yes |
| 93.RD | Development of an Ebolavirus Sudan Vaccine Utilizing a Live Vesicular Stomatitis Virus Chimera Platform Contract A10322 - 324,941 | $324,941 | Yes |
| 93.394 | Cancer Detection and Diagnosis Research | $318,870 | Yes |
| 93.RD | The breadth of cross-reactivity of T cell responses elicited by different vaccination regimensmeasured against different Sarbeco and Merbeco viral sequences | $314,076 | Yes |
| 93.384 | Protect against Emergent Alphaviruses through Computation | $305,205 | Yes |
What findings did the auditor report?
The reference and the requirement letter are the ones the auditor used. The finding text itself is not reproduced here; the FAC report linked above carries it in full.
The most recent report lists no finding.
Form 990 and IRS registration
Form 990 "accounting fees" (Part IX line 11c) cover all accounting services reported by the organization and are not the price of an audit engagement.
- Most recent return
- 990 for 2024-12
- Total revenue
- $84,154,783
- Total assets
- $62,503,266
- Accounting fees (Part IX line 11c)
- $350,596
- Paid preparer
- DELOITTE TAX LLP
- IRS object id
- 202542769349301114
- Exempt under
- 501(c)(3)
- Ruling year
- 1989
- BMF release
- 2026-09-17
Read next
- CPA firms that audit California nonprofits
- California single audit statistics
- California nonprofit audit requirements
How we computed this
Every row comes from the Federal Audit Clearinghouse record named beside it, one report per audit year, with a resubmission superseding the filing it replaces. The auditor is the one named on that filing — it is not a statement about who audits LA JOLLA INSTITUTE FOR IMMUNOLOGY now. Form 990 figures come from the IRS e-filed return named by its object id. This page exists because the organization filed at least two single audits, or one with a finding.
Cite this page
AuditRadar. “LA JOLLA INSTITUTE FOR IMMUNOLOGY Single Audits and Findings (CA).” https://getauditradar.com/single-audits/ca/la-jolla-institute-for-immunology-330328688/. Data as of 2026-09-18.